about
Suppressive oligodeoxynucleotides reduce lung cancer susceptibility in mice with silicosis.TLR-based immune adjuvants.Suppressive oligodeoxynucleotides promote the generation of regulatory T cells by inhibiting STAT1 phosphorylation.CpG DNA as a vaccine adjuvant.Suppressive oligodeoxynucleotides promote the development of Th17 cells.Synthetic oligodeoxynucleotides containing suppressive TTAGGG motifs inhibit AIM2 inflammasome activation.IRF5 and IRF8 modulate the CAL-1 human plasmacytoid dendritic cell line response following TLR9 ligation.Linezolid, vancomycin and daptomycin modulate cytokine production, Toll-like receptors and phagocytosis in a human in vitro model of sepsis.Antifungal antibiotics modulate the pro-inflammatory cytokine production and phagocytic activity of human monocytes in an in vitro sepsis model.Antibiotics regulate the immune response in both presence and absence of lipopolysaccharide through modulation of Toll-like receptors, cytokine production and phagocytosis in vitro.[Pediatric emergence agitation].Prevention and Therapy of Pediatric Emergence Delirium: A National Survey.Suppressive oligodeoxynucleotides containing TTAGGG motifs inhibit cGAS activation in human monocytes.Human plasmacytoid dentritic cells elicit a Type I Interferon response by sensing DNA via the cGAS-STING signaling pathway.Interprofessional two-man team approach for interhospital transport of ARDS-patients under extracorporeal membrane oxygenation: a 10 years retrospective observational cohort studyIGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical stagingElectrocardiography-controlled central venous catheter tip positioning in patients with atrial fibrillationExtensive Therapeutic Drug Monitoring of Colistin in Critically Ill Patients Reveals Undetected Risks
P50
Q33585368-5D87E00B-DEB0-4868-8772-12641EA63192Q34400322-5E533DD8-F5DB-4F42-AA81-6F33336F4CDCQ34602996-41600F8F-74E5-40AD-8941-4F224233593AQ35025722-F31E2232-A9D3-41A3-B2E6-3E11EC6C8236Q36976397-CFE603B6-3AF7-4536-89A3-D2273A0B10A6Q37426823-0DEC348B-E218-46CD-8710-CAF0912B604CQ38295035-EAD98C8E-F4E6-4501-B9A3-40BBC7D94059Q38904168-0DE7A212-396C-4DFF-A571-879CC676ECDFQ38962604-BDA4E563-0533-4E60-85EB-116F8F4959F3Q39062588-A2DC1149-56AA-4BA3-AEC5-067A0F3CB6A3Q41730822-C05597CF-B944-4D87-8F0A-BE8AEDBDD71DQ47337048-466A5097-034C-4424-9EDB-0B4D9530AFAEQ48160898-9A669F46-C914-4565-976E-547EE2CB727CQ54197779-1582812D-64E8-428C-AAB4-4F26FC409E92Q61804720-6771CFB9-7FBF-4043-ABBA-18519386E785Q82137147-4259C4AE-5CA2-4B5C-9779-1317D0814BAAQ87985858-47EFE917-6B78-4F34-BA46-8B48575D0D8EQ90400600-765F3C53-C8E9-4DB5-8CD0-F0A8725882DE
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Christian Bode
@en
Christian Bode
@nl
type
label
Christian Bode
@en
Christian Bode
@nl
prefLabel
Christian Bode
@en
Christian Bode
@nl
P31
P496
0000-0002-0830-870X